$427.50▲ 4.26 (1.01%)
Real-time prices · US MarketsQ·Score
Buy
8.4 / 10
High-quality business with 23% return on equity and 33% profit margins.
Quality
9.3
Health
8.4
Growth
7.8
Valuation
8.1
Sentiment
8
Analyst Target
$548.39
▲ +28.3% from current
Price Chart
Latest News
- Vortex Energy Announces Intent to Advance Next Phase of Technical Work at the Robinsons River Salt Project and Engages Lonquist
- Why CRISPR Therapeutics (CRSP) Is Down 10.1% After Casgevy’s Strong Early Launch Metrics And Earnings Hopes
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
Fundamentals
Trailing P/E
27.9×
price-to-earnings
Forward P/E
19.6×
next 12 months est.
Market Cap
$108.7B
market capitalization
Div Yield
—
dividend yield
Profit Margin
32.9%
net profit margin
Gross Margin
53.7%
revenue minus COGS
ROE
22.5%
return on equity
Beta
0.37
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$363 — $509
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is VRTX a good stock to buy right now?
Based on our Q·Score of 8.4/10, Vertex Pharmaceuticals Incorpor is rated "Buy". High-quality business with 23% return on equity and 33% profit margins. This analysis is based on fundamentals, analyst consensus, and valuation data, and should not be considered financial advice.
What is the analyst price target for VRTX?
The consensus price target for VRTX is $548.39, based on the recommendations of 28 Wall Street analysts. This implies 28.3% upside from the current price of $427.50.
Is VRTX overvalued or undervalued?
Vertex Pharmaceuticals Incorpor (VRTX) appears reasonably valued or undervalued relative to analyst targets and sector peers. It trades at a 19.6× forward P/E ratio. Analysts see 28% upside to their $548.39 consensus target.
When does Vertex Pharmaceuticals Incorpor report its next earnings?
Vertex Pharmaceuticals Incorpor is scheduled to report earnings in 4 days, on May 4, 2026.
What is Vertex Pharmaceuticals Incorpor's profit margin?
Vertex Pharmaceuticals Incorpor has a net profit margin of 32.9%, which is considered high and reflects strong pricing power. Its gross margin stands at 53.7%, indicating a high-margin business model.
Is Vertex Pharmaceuticals Incorpor's revenue growing?
Vertex Pharmaceuticals Incorpor is reporting modest revenue growth of 9.5%. Earnings are also growing at 32.9%, indicating improving profitability.
How much debt does Vertex Pharmaceuticals Incorpor have?
Vertex Pharmaceuticals Incorpor has a debt-to-equity ratio of 0.11×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 2.90×, indicating comfortable short-term liquidity.